Introduction

Dr. McHale discusses the key findings from the Master Trial, which evaluated the concept of stopping treatment for multiple myeloma patients who achieved deep responses. While patients with low-risk genetic abnormalities achieved excellent survival rates, stopping therapy may not be the ideal approach for those with higher risk genetic abnormalities.